PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

X. Le, Y. Yu, Y. Zhao,D. Planchard, Y. Cheng, X. Li,S. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess,S. Kitazono, N. Leighl,B. Gao,O. Juan-Vidal,A. J. de Langen, J. Mazieres,M. Perol, Y. Jiang, T. Hu, J. Huang, N. Baio,L. Musib,M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, J. Wang

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited 0|Views4

Key words

Firmonertinib or furmonertinib,EGFR uncommon mutations,EGFR PACC mutations

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined